Unicycive Therapeutics Inc. (NASDAQ:UNCY) saw its stock price collapse in premarket trading Tuesday following the U.S. Food and Drug Administration's second complete response letter (CRL) for the company's lead drug candidate, oxylanthanum carbonate (OLC), which is being developed to treat hyperphosphatemia in chronic kidney disease patients on dialysis. The stock traded at $4.02 before the opening bell, representing a 47.76% decline from Monday's close of $7.70. Trading volume surged to 5.78 million shares, more than four times the average daily volume of 1.27 million shares.
The FDA's latest CRL, issued on Monday, June 29, 2026, focuses on deficiencies at a third-party manufacturing facility. Notably, the agency did not raise any concerns regarding the drug's safety or efficacy, and no additional clinical data were requested. This marks the second time the FDA has rejected the new drug application (NDA) for OLC, with the first CRL issued in June 2025 also citing manufacturing issues at the same vendor.
Chief Executive Officer Shalabh Gupta expressed confidence in the drug's profile, stating, "We remain confident in the efficacy and safety of OLC." He added that the company plans to "expeditiously resubmit the NDA" after addressing the FDA's concerns. The company noted that the FDA had not conducted an inspection of the manufacturing vendor during its review of the resubmitted application, and label negotiations were ongoing as of June 29.
The premarket sell-off has significantly compressed the company's market valuation. Based on the $4.02 share price, the equity market capitalization stands at approximately $107 million. After subtracting the company's reported cash and marketable securities of $57.1 million (as of May 11, 2026), the implied value of the business excluding cash is roughly $50 million. This valuation is particularly stark when compared to the company's at-the-market (ATM) offering program. On June 5, 2026, Unicycive filed an ATM registration for $50 million in common stock, an amount that now represents nearly half of the company's premarket equity value net of cash.
Investors are now closely watching the timeline for the FDA's re-inspection of the third-party manufacturer and the associated costs. The company has previously stated that its cash position is sufficient to fund planned operations into 2027. However, the delay in approval could increase cash burn as Unicycive maintains launch preparations without a clear path to revenue. The company sold 3.12 million shares in the first quarter under its existing sales agreement at an average price of $6.46, generating net proceeds of approximately $19.6 million after commissions. The ATM program's limit was raised to $150 million on June 5.
Analyst sentiment had been overwhelmingly positive ahead of the CRL. H.C. Wainwright maintained a Buy rating and a $22 price target on Monday, noting that the resubmission carried less risk due to the manufacturing-focused nature of the prior rejection. According to Google Finance, six analyst ratings published in the last three months were all Buy, with an average price target of $41.50. The lowest target among analysts was $18, while the highest reached $90.
Broader market conditions were supportive on Monday, with the Nasdaq Composite advancing 2.07% to close at 25,820.14, and the Russell 2000 gaining to 3,010.42. Unicycive's sharp decline stands in stark contrast to the overall market strength.
Unicycive's OLC is designed to treat hyperphosphatemia, a condition common in dialysis patients. Current treatments include Sanofi's Renvela and Akebia Therapeutics' Auryxia, both of which require a high daily pill burden. Unicycive has positioned OLC as a potential improvement, aiming to reduce the number and size of pills patients need to take.
The key question for investors is how quickly the company can resolve the manufacturing issues and resubmit the NDA. With no safety or efficacy concerns, the path to approval hinges on the FDA's inspection timeline. Until then, the stock's valuation will likely remain under pressure as the market weighs the cash burn rate, dilution risk from the ATM program, and the ultimate commercial potential of OLC.
